Craig L. Slingluff Jr. MD
Surgical Oncology (Other than Breast)
Professor of Surgery, University VA School of Medicine
Join to view full profile
Dept of Surgery, University of Virginia PO Box 800709Charlottesville, VA 22908
Phone+1 434-924-9311
Dr. Slingluff is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalResidency, Surgery, 1984 - 1991
University of Virginia School of MedicineClass of 1984
Certifications & Licensure
VA State Medical License 1991 - 2028
American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
Clinical Trials
- Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
- Vaccine Therapy in Treating Patients With Metastatic Melanoma
- Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Start of enrollment: 2005 May 09
Publications & Presentations
PubMed
- Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.Emily K Ninmer, Hong Zhu, Amrita Sarkar, Kimberly A Chianese-Bullock, Merrick I Ross
Clinical Cancer Research. 2026-06-15 - Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, Andrew S Poklepovic, Varinder Kaur
Cancer Research Communications. 2026-04-01 - 15 citationsPD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.Lestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino, Andressa Dias Costa, Matthew H G Katz
Clinical Cancer Research. 2024-02-01
Press Mentions
UVA Health Launches World's 1st Ultrasound Immunotherapy Cancer CenterMay 11th, 2022- World’s First Focused Ultrasound Cancer Immunotherapy Center Will Be at UVAMay 11th, 2022
Q&A: Cancer Death Rates Are Falling Nationally. Here’s What’s Happening at UVAJanuary 10th, 2020
Grant Support
- Postdoctoral Training Grant for MDs in Surgical Oncology ResearchUNIVERSITY OF VIRGINIA2011–2031
- Melanoma Vaccines Using Mhc-Associated PeptidesNational Cancer Institute2002–2011
- Phase 2: CCI-779 In Combination With Bevacizumab In Stage III Or IV MelanomaNational Center For Research Resources2010
- Intratumoral Interferon Gamma During Vaccination In Metastatic MelanomaNational Center For Research Resources2010
- A Multipeptide Vaccine In Melanoma Patients With Evaluation Of Injection SiteNational Center For Research Resources2009–2010
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: